The PREFER study: Dosing recommendations for biphasic insulin aspart 30, insulin detemir and insulin aspart using treat-to-target titration

被引：0
|
作者：
Gallwitz, B.
Prager, R.
Kaiser, M.
Binz, K.
Liebl, A.
机构：
[1] Univ Tubingen, Dept Med, Tubingen, Germany
[2] L Boltzmann Res Inst Metab Dis & Nutr, Dept Endocrinol & Metab, Vienna, Austria
[3] Novo Nordisk Pharm GmbH, Mainz, Germany
[4] Triemli City Hosp, Dept Diabet, Zurich, Switzerland
[5] Ctr Diabet & Metabol, Dept Diabet, Bad Heilbrunn, Germany
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0999
引用
收藏
页码：611 / 612
页数：2
相关论文
共 50 条
  • [1] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
    Liebl, Andreas
    Prager, Rudolf
    Kaiser, Marcel
    Binz, Katharina
    Gallwitz, Baptist
    DIABETES, 2006, 55 : A460 - A461
  • [2] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (lDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
    Liebl, A.
    Compion, G.
    Prager, R.
    Binz, K.
    Kaiser, M.
    Gallwitz, B.
    DIABETIC MEDICINE, 2007, 24 : 75 - 75
  • [3] Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial
    Fulcher, Gregory R.
    Christiansen, Jens Sandahl
    Bantwal, Ganapathi
    Polaszewska-Muszynska, Miroslawa
    Mersebach, Henriette
    Andersen, Thomas H.
    Niskanen, Leo K.
    DIABETES CARE, 2014, 37 (08) : 2084 - 2090
  • [4] Modeling of Pharmacokinetic Profiles of Insulin Aspart and Biphasic Insulin Aspart 30/70
    Kulesh, Victoria S.
    Drai, Roman, V
    Zinnatulina, Bella R.
    Makarenko, Igor E.
    Pilyus, Fedor G.
    Khokhlov, Alexander L.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (09): : 1086 - 1093
  • [5] Postprandial dosing of the "lowmix" biphasic insulin aspart
    Kapitza, C
    Nosek, L
    Lindholm, A
    Leth, G
    Codony, SG
    Heise, TC
    DIABETOLOGIA, 2001, 44 : A211 - A211
  • [6] A Comparison of Pharmacokinetics and Pharmacodynamics of Insulin Aspart, Biphasic Insulin Aspart 70, Biphasic Insulin Aspart 50, and Human Insulin: A Randomized, Quadruple Crossover Study
    Ma, Zhulin
    Parkner, Tina
    Frystyk, Jan
    Laursen, Torben
    Lauritzen, Torsten
    Christiansen, Jens Sandahl
    DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (07) : 589 - 595
  • [7] Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: The PRIEFER study
    Liebl, Andreas
    Prager, Rudolf
    Kaiser, Marcel
    Binz, Katharina
    Gallwitz, Baptist
    DIABETES, 2006, 55 : A123 - A123
  • [8] Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naive subjects with type 2 diabetes
    Yang, Wenying
    Xu, Xiangjin
    Liu, Xiaomin
    Yang, Gangyi
    Seino, Yutaka
    Andersen, Henning
    Jinnouchi, Hideaki
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (12) : 1599 - 1608
  • [9] The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%
    Liebl, A.
    Prager, R.
    Kaiser, M.
    Binz, K.
    Gailwitz, B.
    DIABETOLOGIA, 2006, 49 : 610 - 611
  • [10] Insulin aspart and biphasic insulin aspart provide flexible and convenient administration
    Drugs & Therapy Perspectives, 2003, 19 (2) : 1 - 4
12345